艾立康

Ailikang Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of high-end inhalation drug delivery systems. The company focuses on treating chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) through innovative drug-device combinations. Its technology platform encompasses dry powder inhalers (DPI), metered-dose inhalers (MDI), and nasal sprays, addressing the technical challenges of pulmonary drug delivery. Ailikang's pipeline includes several advanced programs, such as triple and dual combination therapies, aimed at providing high-quality alternatives to global blockbuster respiratory drugs. By integrating formulation science with device engineering, the company seeks to improve patient outcomes and accessibility in the respiratory therapeutic area.